Omnicell Introduces OmniSphere Platform, Stock to Gain
Omnicell introduces OmniSphere. Additionally, the company showcases a full portfolio of outcomes-centric solutions at the ASHP Midyear 2024.
Why Is Omnicell (OMCL) Down 0.4% Since Last Earnings Report?
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock?
Wall Street Analysts Believe Omnicell (OMCL) Could Rally 26.73%: Here's is How to Trade
The mean of analysts' price targets for Omnicell (OMCL) points to a 26.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why You Should Add OMCL Stock to Your Portfolio Now
A robust Advanced Services portfolio and long-term growth initiatives bode well for Omnicell.
Surging Earnings Estimates Signal Upside for Omnicell (OMCL) Stock
Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Omnicell Q3 Earnings: Look At The Growth Segment
Omnicell, Inc. is a pharmacy management provider working towards the goal of an autonomous pharmacy. Q3 earnings looked weak on the surface with revenue and EBITDA down, but results by business show a strong and growing service business. Omnicell has unique technology with strong market tailwinds that support long-term growth.
OMCL Stock Soars on Q3 Earnings & Revenue Beat, '24 EPS View Raised
Omnicell continues its trend of impressive results in the third quarter of 2024.
Omnicell, Inc. (OMCL) Soars to 52-Week High, Time to Cash Out?
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Omnicell, Inc. (OMCL) Q3 2024 Earnings Call Transcript
Omnicell, Inc. (NASDAQ:OMCL ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Kathleen Neiman - Senior Vice President, Investor Relations Randall Lipps - Founder, Chairman, President & Chief Executive Officer Nchacha Etta - Executive Vice President & Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Jessica Tassan - Piper Sandler Allen Lutz - Bank of America Stephanie Davis - Barclays Anne Samuel - JPMorgan Scott Schoenhaus - KeyBanc Capital Markets Bill Sutherland - The Benchmark Company Stan Berenshteyn - Wells Fargo David Larsen - BTIG Operator Thank you for standing by. My name is John, and I'll be your conference operator today.
Omnicell (OMCL) Beats Q3 Earnings and Revenue Estimates
Omnicell (OMCL) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.62 per share a year ago.
Zacks Industry Outlook Medical Systems, 10x Genomics and Omnicell
Medical Systems, 10x Genomics and Omnicell have been highlighted in this Industry Outlook article.
Omnicell: Innovating Medication Management and Driving Growth in the Healthcare Sector
In this ROBO Global Robotics and Automation Index spotlight, we focus on Omnicell Inc (OMCL). The index underlies the $1.13 billion ROBO Global Robotics and Automation ETF (ROBO).
